Insulet (MEX:PODD) ROE % Adjusted to Book Value: 1.99% (As of Mar. 2026)

Insulet MEX:PODD 80 ROE % Adjusted to Book Value is 1.99% as of Mar. 2026. GuruFocus rates MEX:PODD with a GF Score™ of 80/100 and a GF Value™ of MXN6,365.57 (Significantly Undervalued).

Insulet's ROE % for the quarter that ended in Mar. 2026 was 25.88%. Insulet's PB Ratio for the quarter that ended in Mar. 2026 was 12.98. Insulet's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 1.99%.

Insulet ROE % Adjusted to Book Value Related Terms

Insulet ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Insulet's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet ROE % Adjusted to Book Value Chart

Insulet Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.08

0.02

1.77

3.18

1.09

Insulet Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.82	0.42	1.45	1.78	1.99

MEX:PODD vs GMED, PEN, BRKR: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, Insulet's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insulet ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Insulet's ROE % Adjusted to Book Value falls into.

Save Embed

80GF Score

Insulet Corp MEX:PODD

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Insulet ROE % Adjusted to Book Value Calculation

Insulet's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	16.93%	/	15.58
	=	1.09%

Insulet's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	25.88%	/	12.98
	=	1.99%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 1.99% mean?

Insulet (MEX:PODD) has a ROE % Adjusted to Book Value of 1.99% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Insulet and its competitors.

Is Insulet's ROE % Adjusted to Book Value too high?

Insulet's current ROE % Adjusted to Book Value is 1.99%. Overall, Insulet has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Insulet's ROE % Adjusted to Book Value compare to GMED and PEN?

Insulet's ROE % Adjusted to Book Value of 1.99% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?

A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Insulet and its competitors. Insulet's current ROE % Adjusted to Book Value is 1.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Insulet stock overvalued right now?

Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN6,365.57, compared to a current price of MXN2,548.13 — trading 60% below its estimated fair value. The current ROE % Adjusted to Book Value is 1.99%. Insulet's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Insulet (MEX:PODD), the current ROE % Adjusted to Book Value is 1.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MEX:PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of MXN2,548.13 is trading 60% below its estimated GF Value™ of MXN6,365.57. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for MEX:PODD:

ROE % Adjusted to Book Value: 1.99%
GF Value™: MXN6,365.57 vs. price of MXN2,548.13 (60% below fair value)
GF Score™: 80/100

No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies GMED PEN BRKR GKOS BIO LIVN ZBH IRTC HAE ITGR ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges PODD:USA 1PODD:Italy GOV:Germany P2OD34:Brazil

Address 100 Nagog Park, Acton, MA, USA, 01720

Website https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

80GF Score

Get the complete analysis for MEX:PODD

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,548.13

Price

MXN6,365.57

GF Value

View MEX:PODD Analysis

See ROE % Adjusted to Book Value data for all stocks →